- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Top 5 Most-Read Diabetes Content of 2022
The top 5 most-read articles about diabetes featured stories on FDA approvals, drug prices, and the effectiveness of vitamin D in diabetes prevention, among others.
The top 5 most-read articles about diabetes that were published on AJMC.com included topics such as disparities in emergency department (ED) use in patients with diabetes, including cardiovascular health in treatment of diabetes, and the effectiveness of vitamins in preventing type 2 diabetes (T2D).
Here are the most-read articles about diabetes for 2022.
5. Study Outlines Disparities in ED Use for Patients With Diabetes
Wide disparities in the use of the ED in patients with diabetes between 2008 and 2017 were found in a cross-sectional study, whose results were reported in this article. The study found that all-cause diabetes ED visits increased 55.6%, from 257.6 to 400.8 visits per 10,000 adults, from 2008 to 2017.
4. Budget Bill Allowing Medicare to Negotiate Drug Prices Heads to House
The Inflation Reduction Act was approved by the Senate and moved to a House vote in August 2022, according to this article published in the same month. The Inflation Reduction Act aimed to give Medicare the power to negotiate drug prices for their beneficiaries. The Act would also cap the cost of insulin to $35 for those on Medicare.
3. Cardiologists Must “Get Into the Game” With Novel Agents in Patients With Diabetes
In this article, Erin D. Michos, MD, MHS, and Pam R. Taub, MD, discussed in a pair of talks how going beyond glucose-lowering therapies to include medications that offer cardiovascular benefits should be required in the treatment of diabetes. This article, which was a part of AJMC’s coverage of 2022 Congress of the American Society for Preventive Cardiology held in Kentucky, outlines the multipronged approach the two speakers discussed at their respective symposiums.
2. FDA Approves Eli Lilly’s Tirzepatide for T2D
Tizepatide was approved by the FDA after it demonstrated that it was effective in improving glycemic control for patients with T2D. The medicine, which was recommended to be used alongside diet and exercise, activates the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors and is administered through a weekly injection.
1. Trial: Vitamin D Supplementation Yielded No Preventive Benefits in T2D
A randomized controlled trial found that those at high risk for T2D did not have any preventive benefits from taking supplements of vitamin D. A total of 12.5% of the 630 participants who received vitamin D developed T2D compared with 14.2% of the 626 patients who received a placebo (HR, 0.87; 95% CI, 0.67-1.17).
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen
